Academic Journal
Superior effect of adalimumab versus secukinumab on ultrasound-confirmed synovitis in psoriatic arthritis: comprehensive evidence from musculoskeletal ultrasound and clinical assessments
| Title: | Superior effect of adalimumab versus secukinumab on ultrasound-confirmed synovitis in psoriatic arthritis: comprehensive evidence from musculoskeletal ultrasound and clinical assessments |
|---|---|
| Authors: | Yiyi Wang, Yue Xiao, Lingyan Zhang, Furong Li, Hongxiang Hu, Xiya Peng, Jingya Gao, Min Yang, Wei Yan, Li Qiu, Wei Li |
| Source: | Journal of Dermatological Treatment, Vol 35, Iss 1 (2024) |
| Publisher Information: | Taylor & Francis Group, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Dermatology |
| Subject Terms: | Psoriatic arthritis, secukinumab, adalimumab, clinical efficacy, ultrasound evaluation, Dermatology, RL1-803 |
| More Details: | Background and objectives: Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disorder affecting 30% of psoriatic patients. Effective treatment, especially with biologics like IL-17 and TNF inhibitors, is vital for improving patient outcomes. This study aimed to compare the efficacy of secukinumab and adalimumab in PsA patients through clinical and ultrasonographic evaluations.Materials and methods: We enrolled 116 PsA patients, with 58 patients receiving secukinumab and 58 receiving adalimumab. Regular follow-ups were conducted at weeks 4, 12, 24, and 52. The primary outcome was the proportion of patients achieving at least a 20% improvement in the ACR response (ACR20) at week 12, with additional evaluations for axial arthritis, enthesitis, skin involvement, minimal disease activity, health assessment questionnaire, and ultrasound changes.Results: There was no significant difference in ACR20 response between the two groups at week 12 (OR: 0.59, 95% CI: 0.26–1.37, p = 0.22). However, secukinumab demonstrated superior efficacy in achieving Psoriasis Area and Severity Index (PASI)90 (OR: 2.25, 95%CI: 1.07–4.74, p = 0.03), while adalimumab showed better improvement in ultrasound synovitis count (β: 0.94, 95%CI: 0.09–1.79, p = 0.03) and synovitis PD signal (β: 0.20, 95%CI: 0.03–0.36, p = 0.02).Conclusions: In conclusion, both treatments were highly effective for PsA, with secukinumab being more suitable for severe skin involvement and adalimumab for significant ultrasound-confirmed synovitis. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 09546634 1471-1753 0954-6634 |
| Relation: | https://doaj.org/toc/0954-6634; https://doaj.org/toc/1471-1753 |
| DOI: | 10.1080/09546634.2024.2411849 |
| Access URL: | https://doaj.org/article/bce3f39406de4523b9cb5314736aee95 |
| Accession Number: | edsdoj.bce3f39406de4523b9cb5314736aee95 |
| Database: | Directory of Open Access Journals |
| Full text is not displayed to guests. | Login for full access. |
| ISSN: | 09546634 14711753 |
|---|---|
| DOI: | 10.1080/09546634.2024.2411849 |
| Published in: | Journal of Dermatological Treatment |
| Language: | English |